Tags : Alzheimer Disease

Clinical Trials

Novo Nordisk to Initiate a P-lll Study of Semaglutide to

Shots: Novo Nordisk plans to initiate a pivotal P-llla program to evaluate the efficacy and safety of Semaglutide (oral, 14mg, qd) vs PBO in 3,700 patients with AD with the anticipated initiation in H1’21 The decision follows the evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular […]Read More

Pharma

PostEra Collaborates with NeuroLucent to Identify Therapies for Alzheimer’s Disease

Shots: NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate PostEra will use its ML technology to optimize NeuroLucent’s lead compounds through a series of design make test cycles that has previously been shown to accelerate medicinal chemistry campaigns PostEra […]Read More